A Phase 1B Study of B-701 in Combination With Pembrolizumab in Relapsed or Refractory Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Trial Profile

A Phase 1B Study of B-701 in Combination With Pembrolizumab in Relapsed or Refractory Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs B 701 (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jun 2017 Status changed from active, no longer recruiting to discontinued.
    • 27 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Jan 2017 Planned End Date changed from 1 Oct 2022 to 1 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top